Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors

Adv Exp Med Biol. 1992:324:115-29. doi: 10.1007/978-1-4615-3398-6_12.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary*
  • Dogs
  • Drug Screening Assays, Antitumor
  • Etidronic Acid / therapeutic use*
  • Growth Substances / physiology
  • Humans
  • Male
  • Neoplasm Proteins / physiology
  • Organometallic Compounds / therapeutic use*
  • Organophosphorus Compounds / therapeutic use*
  • Palliative Care
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology*
  • Radioisotopes / administration & dosage
  • Radioisotopes / pharmacokinetics
  • Radioisotopes / therapeutic use*
  • Radionuclide Imaging
  • Rhenium / therapeutic use*
  • Samarium / administration & dosage
  • Samarium / pharmacokinetics
  • Samarium / therapeutic use*
  • Suramin / adverse effects
  • Suramin / therapeutic use*

Substances

  • Growth Substances
  • Neoplasm Proteins
  • Organometallic Compounds
  • Organophosphorus Compounds
  • Radioisotopes
  • Samarium
  • Suramin
  • Rhenium
  • samarium Sm-153 lexidronam
  • Prostate-Specific Antigen
  • Etidronic Acid